Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients
NCT ID: NCT03647813
Last Updated: 2018-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
44 participants
INTERVENTIONAL
2016-07-01
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Photobiomodulation on ph and Salivary Flow
NCT05413993
Photobiomodulation in Salivary Production of Patients With Xerostomy
NCT03632096
Photobiomodulation on the Salivary Glands of Patients With Xerostomia Induced by the Use of Benzodiazepines
NCT05443022
Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis Patients With Xerostomia
NCT06476223
Effect of Photobiomodulation for Patients With Xerostomia
NCT05336981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Photobiomodulation group
Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
Photobiomodulation
Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
Placebo group
Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
Placebo
The same laser protocol was followed but with the device switched off.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Photobiomodulation
Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
Placebo
The same laser protocol was followed but with the device switched off.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hb\> 10.9 g / dl and Hematocrit\> 33;
* Absence of acute systemic infectious processes;
* Blood pressure \<140 mmHg and PAd \<90 mmHg in at least two measurements in two subsequent dialysis;
* No hypervolemia;
* Patients over 18 years-old;
* Signed a statement of informed consent.
Exclusion Criteria
* Hemodynamic instability, signs and symptoms of uremic syndrome related to the cardiovascular and neurological systems;
* Presence of acute systemic infectious processes;
* Presence of acute cardiovascular disease, systolic blood pressure \> 141 mmHg and / or diastolic blood pressure \> 91 mmHg;
* Significant anemia (Hb \<11 g / dl and Hto \<33%);
* Photosensitivity;
* Pregnancy.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Nove de Julho
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandra Kalil Bussadori
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Vanessa
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.